Evidence map›Paper›PMID 31359874›Full record

ArticleAntiviral therapy2019

Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV.

Julia B Balmaceda, Julia Aepfelbacher, Olivia Belliveau, Chloe S Chaudhury, Cheryl Chairez, Mary McLaughlin, Rachel Silk, Chloe Gross, Sarah Kattakuzhy, Elana Rosenthal and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents.Journal of clinical and translational hepatology · 2021
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Julia B BalmacedaNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Julia AepfelbacherNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Olivia BelliveauNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Chloe S ChaudhuryNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Cheryl ChairezNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Mary McLaughlinNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Rachel SilkDivision of Clinical Care and Research, Institute of Human Virology, Department of Medicine, University of Maryland, Baltimore, MD, USA.
Chloe GrossDivision of Clinical Care and Research, Institute of Human Virology, Department of Medicine, University of Maryland, Baltimore, MD, USA.
Sarah KattakuzhyDivision of Clinical Care and Research, Institute of Human Virology, Department of Medicine, University of Maryland, Baltimore, MD, USA.
Elana RosenthalDivision of Clinical Care and Research, Institute of Human Virology, Department of Medicine, University of Maryland, Baltimore, MD, USA.
Shyam KottililDivision of Clinical Care and Research, Institute of Human Virology, Department of Medicine, University of Maryland, Baltimore, MD, USA.
David E KleinerNational Cancer Institute, NIH, Bethesda, MD, USA.
Colleen HadiganNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
National Institute of Allergy and Infectious Diseases · USUniversity of Maryland, Baltimore · USNational Cancer Institute · US

Funding

Postmortem PathologyZICBC010685 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLEINER, DAVID ERWIN · 2009 to 2025
$14.3M
Intramural NIH HHS ZIC BC010685
6 · The paper itself

Abstract

backgroundWhile acute changes in hepatic fibrosis are recognized shortly after achieving sustained virological response (SVR) using direct-acting antiviral therapies, long-term outcomes for the growing population of successfully treated patients with HCV remain uncertain. The aim of this study is to characterize long-term changes in fibrosis following SVR in patients with and without HIV and to identify potential factors associated with progression or regression of fibrosis.

methodsWe completed a prospective longitudinal study of 162 subjects with HCV (34% HIV-coinfected) with pre-treatment fibrosis stage determined by liver biopsy and post-SVR transient elastography. Progression of fibrosis was defined as a two-stage or greater increase in fibrosis, while regression was defined as a two-stage or greater decrease at last follow-up. The median duration of follow-up was 4.1 years.

resultsFibrosis progression occurred in 4% of subjects while regression occurred in 7% and 89% were stable and did not differ by HIV coinfection. Fibrosis progression was associated with increased body mass index (BMI), hepatic steatosis and smoking pack-years. In a multivariable logistic regression, HIV coinfection (P=0.009), lower steatosis score (P<0.05) and lower smoking pack-years (P=0.0007) were associated with a lower fibrosis score at last follow-up.

conclusionsWe identify potentially important relationships between BMI, hepatic steatosis and smoking, and changes in hepatic fibrosis post-SVR in patients with and without HIV coinfection. Attention to modifiable risk factors such as body weight and smoking may reduce the risk of liver disease progression in the growing population of successfully treated chronic HCV patients.

Identifiers

PMID31359874
PMCPMC8296308
OpenAlexW2966513821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.